Diagnosis of HIV-1 infection by PCR with two primer pairs. 1993

E Quirós, and F García, and I González, and T Cabezas, and M C Bernal, and M C Maroto
Department of Microbiology, School of Medicine of Granada, Spain.

We have used two different primer pairs to assess HIV-1 infection of peripheral blood mononuclear cells (PBMC) by polymerase chain reaction (PCR). The study was carried out on 150 individuals: 50 seronegative individuals without risk behaviours for HIV-1 infection, 50 individuals with risk-behaviours but seronegative for HIV-1 and 50 patients with risk-behaviours who were HIV-1 seropositive. Discordances were found between the two primer pairs (SK38/39; SK68/69) in 3 cases. In the non-risk seronegative group, one specimen was scored positive with only one primer pair (SK38/SK39); all the samples belonging to seropositive individuals were found to be positive for HIV-1 DNA using both primer pairs; in the seronegative at risk group 2 samples were positive with only one primer pair (SK38/SK39), and 4 samples were found positive by both primer pairs (SK38/39 & SK68/69). Our study demonstrates that discrepant results take place with relatively high frequency; we propose that all specimens should be tested twice using at least two different primer pairs.

UI MeSH Term Description Entries
D008297 Male Males
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012309 Risk-Taking Undertaking a task involving a challenge for achievement or a desirable goal in which there is a lack of certainty or a fear of failure. It may also include the exhibiting of certain behaviors whose outcomes may present a risk to the individual or to those associated with him or her. Risk Behavior,Behavior, Risk,Behaviors, Risk,Risk Behaviors,Risk Taking
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016133 Polymerase Chain Reaction In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships. Anchored PCR,Inverse PCR,Nested PCR,PCR,Anchored Polymerase Chain Reaction,Inverse Polymerase Chain Reaction,Nested Polymerase Chain Reaction,PCR, Anchored,PCR, Inverse,PCR, Nested,Polymerase Chain Reactions,Reaction, Polymerase Chain,Reactions, Polymerase Chain
D017931 DNA Primers Short sequences (generally about 10 base pairs) of DNA that are complementary to sequences of messenger RNA and allow reverse transcriptases to start copying the adjacent sequences of mRNA. Primers are used extensively in genetic and molecular biology techniques. DNA Primer,Oligodeoxyribonucleotide Primer,Oligodeoxyribonucleotide Primers,Oligonucleotide Primer,Oligonucleotide Primers,Primer, DNA,Primer, Oligodeoxyribonucleotide,Primer, Oligonucleotide,Primers, DNA,Primers, Oligodeoxyribonucleotide,Primers, Oligonucleotide
D018023 HIV Seronegativity Immune status consisting of non-production of HIV antibodies, as determined by various serological tests. HTLV-III Seronegativity,HIV Seronegativities,HTLV III Seronegativity,HTLV-III Seronegativities,Seronegativities, HIV,Seronegativities, HTLV-III,Seronegativity, HIV,Seronegativity, HTLV-III

Related Publications

E Quirós, and F García, and I González, and T Cabezas, and M C Bernal, and M C Maroto
September 2005, International journal of food microbiology,
E Quirós, and F García, and I González, and T Cabezas, and M C Bernal, and M C Maroto
December 1997, Asian Pacific journal of allergy and immunology,
E Quirós, and F García, and I González, and T Cabezas, and M C Bernal, and M C Maroto
February 1990, AIDS research and human retroviruses,
E Quirós, and F García, and I González, and T Cabezas, and M C Bernal, and M C Maroto
January 1999, Methods in molecular medicine,
E Quirós, and F García, and I González, and T Cabezas, and M C Bernal, and M C Maroto
August 1992, BioTechniques,
E Quirós, and F García, and I González, and T Cabezas, and M C Bernal, and M C Maroto
March 1989, Nucleic acids research,
E Quirós, and F García, and I González, and T Cabezas, and M C Bernal, and M C Maroto
May 1994, BioTechniques,
E Quirós, and F García, and I González, and T Cabezas, and M C Bernal, and M C Maroto
July 1992, Nihon rinsho. Japanese journal of clinical medicine,
E Quirós, and F García, and I González, and T Cabezas, and M C Bernal, and M C Maroto
April 1995, Rinsho byori. The Japanese journal of clinical pathology,
E Quirós, and F García, and I González, and T Cabezas, and M C Bernal, and M C Maroto
February 2006, Molecular biotechnology,
Copied contents to your clipboard!